



Natural Product-Based Antibiotics: Synthesis and Activity against Infections

Guest Editors:

Dr. Veronique Fontaine

Microbiology, Bioorganic and
Macromolecular Chemistry Unit,
Faculty of Pharmacy, Université
Libre de Bruxelles (ULB), 1050
Bruxelles, Belgium

Prof. Dr. Mehdi A. Beniddir

Équipe "Pharmacognosie-Chimie
des Substances Naturelles"
BioCIS, CNRS, Université Paris-
Saclay, 92290 Châtenay-Malabry,
France

Dr. Francois Dufrasne

Microbiology, Bioorganic and
Macromolecular Chemistry Unit,
Faculty of Pharmacy, Université
Libre de Bruxelles (ULB), 1050
Bruxelles, Belgium

Deadline for manuscript
submissions:
closed (31 March 2024)

Message from the Guest Editors

Dear Colleagues,

Multidrug-resistant infections are gradually becoming a major concern for global public health. This threat requires urgent multisectoral actions, including the development of novel anti-infectious strategies and new antibacterial compounds.

Natural products represent a major source of treatment. Over the last 95 years, purified natural antibiotics, or even their derivatives, obtained by synthesis, have also been used, representing the majority of the drugs approved today. So, nature is clearly a dynamic research field that aims to discover and create new antimicrobial compounds.

We hope that this Special Issue will provide you with new opportunities to present your innovative results. This Special Issue aimed to expand our knowledge on natural products-based antimicrobial compounds and their activities to selectively target pathogens.

Keywords: natural products; chemical synthesis; antimicrobial activity; selectivity; cytotoxicity; anti-biofilm activity





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)